Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

ncing activities in the 2012 period reflect the private placement completed in February 2012. The cash flows from financing activities in the 2013 period reflect the direct placement to OrbiMed completed in February 2013, as well as funding under the share purchase agreement with Lincoln Park Capital.

Conference Call and Webcast InformationBioLineRx will hold a conference call to discuss its third quarter 2013 results today, November 13, 2013, at 10:00 a.m. EST. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, www.biolinerx.com, and through www.kcsa.com. A presentation will be provided on BioLineRx's website to accompany management's remarks during the conference call. To dial into the conference call, please dial 1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call at www.biolinerx.com or www.kcsa.com. A dial-in replay of the call will also be available until November 16, 2013. To access the replay, please dial 1-888-254-7270 from the U.S. or +972-3-925-5927 internationally.

(Tables follow)About BioLineRxBioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including:
'/>"/>

SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
9. BioLineRx to Present at 15th International Celiac Disease Symposium
10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
11. BioLineRx Appoints B. J. Bormann to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ --,CuraGen ... interim clinical data on intravenous belinostat,(PXD101), a ... treatment of cancer, are expected to be ... One oral and one poster presentation discussing ...
... WIRE)--Apr 18, 2007 - Critical,Therapeutics, Inc. (Nasdaq: ... a role in chronic inflammatory,autoimmune disease for ... mediator and nuclear DNA-binding protein, will be,published ... Immunology. The,publication demonstrates that HMGB1 is part ...
Cached Medicine Technology:CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... and cardiovascular health as other healthy mature individuals, according ... Journal of Transplantation . The findings may provide some ... professionals caring for them. , Over the past two ... and older has become more common. Given the links ... removal of a kidney could make older donors vulnerable ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
Breaking Medicine News(10 mins):Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3
... Aggression, testosterone and nepotism dont necessarily help one climb ... female can, according to new research on the social ... The study, published today in the journal Proceedings of ... status, reproductive physiology and group dynamics. , ...
... Hopkins researchers question government decision to lower requirements ... -- Challenging a recent U.S. government decision to ... heart transplant hospital, a new Johns Hopkins Medical ... from 10 transplants to 14 transplants a year. ...
... new study from the Monell Center increases understanding ... and vomiting that often afflict patients undergoing chemotherapy. ... new approaches to combat these debilitating side effects. ... nausea and vomiting that accompany chemotherapy treatment, we ...
... 30 AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... AMICAS are scheduled to,address investors at the UBS Global Healthcare Services ... WHEN: -- Tuesday, ... Presentation begins promptly at 11:30 a.m. (Eastern Time), ...
... 2008 Preventative heart healthcare gains strong momentum today ... involvement as the exclusive radiology provider for the High-Risk ... joint research effort to advance the understanding and management ... primary underlying cause of heart attacks and strokes. ...
... to Nutrition on the Go, an,innovative new program from Diet.com, ... 1,700 restaurants nationwide is available in,a flash through your cell ... item., Not cell phone savvy? No worries. You put ... you need help with, then send that info to,DIET1 (34381). ...
Cached Medicine News:Health News:Females decide whether ambitious males float or flounder 2Health News:Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals 2Health News:Explaining chemotherapy-associated nausea 2Health News:AMICAS to Present at UBS Global Healthcare Services Conference 2Health News:NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative 2Health News:Ring Up Instant Nutrition Info via Text Message to DIET1 (34381) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: